Statin use and the risk of 10 cancers

Patricia F. Coogan, Lynn Rosenberg, Brian L. Strom

Research output: Contribution to journalArticle

128 Citations (Scopus)

Abstract

BACKGROUND: Statins affect the proliferation, survival, and migration of cancer cells, and it is thought that they may have chemopreventive properties in humans. The purpose of the present study was to evaluate the association between statin use and various types of cancer in our hospital-based case-control surveillance study. METHODS: Data were collected from patients ages 40-79 years who were admitted to participating hospitals in 3 centers in Philadelphia, New York, and Baltimore from 1991 to 2005. Nurses administered questionnaires to obtain information on medication use and other factors. We compared patients who had any of 10 types of cancer (a total of 4913 patients) with controls admitted for noncancer diagnoses (3900 patients). The following cancers were examined individually: female breast (n = 1185), prostate (n = 1226), colorectal (n = 734), lung (n = 464), bladder (n = 240), leukemia (n = 254), pancreas (n = 220), kidney (n = 226), endometrial (n = 220), and non-Hodgkin lymphoma (n = 144). Logistic regression models were used to estimate odds ratios and 95% confidence intervals among regular statin users compared with never-users. RESULTS: Odds ratios were compatible with 1.0 for all cancer types. For the 4 largest cancer sites (breast, prostate, colorectum, and lung), odds ratios did not vary significantly by duration of statin use. CONCLUSIONS: Statins are among the most commonly used medications, and durations of use are increasing. The present data do not support either positive or negative associations between statin use and the occurrence of 10 cancer types. Cancer incidence should continue to be monitored among statin users.

Original languageEnglish (US)
Pages (from-to)213-219
Number of pages7
JournalEpidemiology
Volume18
Issue number2
DOIs
StatePublished - Mar 1 2007

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Neoplasms
Odds Ratio
Prostate
Logistic Models
Lung
Baltimore
Non-Hodgkin's Lymphoma
Cell Movement
Case-Control Studies
Pancreas
Leukemia
Urinary Bladder
Breast
Nurses
Confidence Intervals
Breast Neoplasms
Kidney
Survival
Incidence

All Science Journal Classification (ASJC) codes

  • Epidemiology

Cite this

Coogan, Patricia F. ; Rosenberg, Lynn ; Strom, Brian L. / Statin use and the risk of 10 cancers. In: Epidemiology. 2007 ; Vol. 18, No. 2. pp. 213-219.
@article{b0130b4b19d64815a563ae4dc533ec9d,
title = "Statin use and the risk of 10 cancers",
abstract = "BACKGROUND: Statins affect the proliferation, survival, and migration of cancer cells, and it is thought that they may have chemopreventive properties in humans. The purpose of the present study was to evaluate the association between statin use and various types of cancer in our hospital-based case-control surveillance study. METHODS: Data were collected from patients ages 40-79 years who were admitted to participating hospitals in 3 centers in Philadelphia, New York, and Baltimore from 1991 to 2005. Nurses administered questionnaires to obtain information on medication use and other factors. We compared patients who had any of 10 types of cancer (a total of 4913 patients) with controls admitted for noncancer diagnoses (3900 patients). The following cancers were examined individually: female breast (n = 1185), prostate (n = 1226), colorectal (n = 734), lung (n = 464), bladder (n = 240), leukemia (n = 254), pancreas (n = 220), kidney (n = 226), endometrial (n = 220), and non-Hodgkin lymphoma (n = 144). Logistic regression models were used to estimate odds ratios and 95{\%} confidence intervals among regular statin users compared with never-users. RESULTS: Odds ratios were compatible with 1.0 for all cancer types. For the 4 largest cancer sites (breast, prostate, colorectum, and lung), odds ratios did not vary significantly by duration of statin use. CONCLUSIONS: Statins are among the most commonly used medications, and durations of use are increasing. The present data do not support either positive or negative associations between statin use and the occurrence of 10 cancer types. Cancer incidence should continue to be monitored among statin users.",
author = "Coogan, {Patricia F.} and Lynn Rosenberg and Strom, {Brian L.}",
year = "2007",
month = "3",
day = "1",
doi = "10.1097/01.ede.0000254694.03027.a1",
language = "English (US)",
volume = "18",
pages = "213--219",
journal = "Epidemiology",
issn = "1044-3983",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

Statin use and the risk of 10 cancers. / Coogan, Patricia F.; Rosenberg, Lynn; Strom, Brian L.

In: Epidemiology, Vol. 18, No. 2, 01.03.2007, p. 213-219.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Statin use and the risk of 10 cancers

AU - Coogan, Patricia F.

AU - Rosenberg, Lynn

AU - Strom, Brian L.

PY - 2007/3/1

Y1 - 2007/3/1

N2 - BACKGROUND: Statins affect the proliferation, survival, and migration of cancer cells, and it is thought that they may have chemopreventive properties in humans. The purpose of the present study was to evaluate the association between statin use and various types of cancer in our hospital-based case-control surveillance study. METHODS: Data were collected from patients ages 40-79 years who were admitted to participating hospitals in 3 centers in Philadelphia, New York, and Baltimore from 1991 to 2005. Nurses administered questionnaires to obtain information on medication use and other factors. We compared patients who had any of 10 types of cancer (a total of 4913 patients) with controls admitted for noncancer diagnoses (3900 patients). The following cancers were examined individually: female breast (n = 1185), prostate (n = 1226), colorectal (n = 734), lung (n = 464), bladder (n = 240), leukemia (n = 254), pancreas (n = 220), kidney (n = 226), endometrial (n = 220), and non-Hodgkin lymphoma (n = 144). Logistic regression models were used to estimate odds ratios and 95% confidence intervals among regular statin users compared with never-users. RESULTS: Odds ratios were compatible with 1.0 for all cancer types. For the 4 largest cancer sites (breast, prostate, colorectum, and lung), odds ratios did not vary significantly by duration of statin use. CONCLUSIONS: Statins are among the most commonly used medications, and durations of use are increasing. The present data do not support either positive or negative associations between statin use and the occurrence of 10 cancer types. Cancer incidence should continue to be monitored among statin users.

AB - BACKGROUND: Statins affect the proliferation, survival, and migration of cancer cells, and it is thought that they may have chemopreventive properties in humans. The purpose of the present study was to evaluate the association between statin use and various types of cancer in our hospital-based case-control surveillance study. METHODS: Data were collected from patients ages 40-79 years who were admitted to participating hospitals in 3 centers in Philadelphia, New York, and Baltimore from 1991 to 2005. Nurses administered questionnaires to obtain information on medication use and other factors. We compared patients who had any of 10 types of cancer (a total of 4913 patients) with controls admitted for noncancer diagnoses (3900 patients). The following cancers were examined individually: female breast (n = 1185), prostate (n = 1226), colorectal (n = 734), lung (n = 464), bladder (n = 240), leukemia (n = 254), pancreas (n = 220), kidney (n = 226), endometrial (n = 220), and non-Hodgkin lymphoma (n = 144). Logistic regression models were used to estimate odds ratios and 95% confidence intervals among regular statin users compared with never-users. RESULTS: Odds ratios were compatible with 1.0 for all cancer types. For the 4 largest cancer sites (breast, prostate, colorectum, and lung), odds ratios did not vary significantly by duration of statin use. CONCLUSIONS: Statins are among the most commonly used medications, and durations of use are increasing. The present data do not support either positive or negative associations between statin use and the occurrence of 10 cancer types. Cancer incidence should continue to be monitored among statin users.

UR - http://www.scopus.com/inward/record.url?scp=33847031748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847031748&partnerID=8YFLogxK

U2 - 10.1097/01.ede.0000254694.03027.a1

DO - 10.1097/01.ede.0000254694.03027.a1

M3 - Article

C2 - 17235211

AN - SCOPUS:33847031748

VL - 18

SP - 213

EP - 219

JO - Epidemiology

JF - Epidemiology

SN - 1044-3983

IS - 2

ER -